Data gathered: September 11
Alternative Data for Biodexa Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 94 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,124 | Sign up | Sign up | Sign up |
| Twitter Followers | 334 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 22 | Sign up | Sign up | Sign up |
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain.
| Price | $5.93 |
| Target Price | Sign up |
| Volume | 55,080 |
| Market Cap | $3.5M |
| Year Range | $5.32 - $53.7 |
| Dividend Yield | 0% |
| PE Ratio | 0 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Nanotechnology Stocks Worth Watching – September 8thSeptember 10 - ETF Daily News |
 |
Best Nanotechnology Stocks Worth Watching – September 3rdSeptember 5 - ETF Daily News |
|
Promising Nanotechnology Stocks Worth Watching – August 31stSeptember 2 - ETF Daily News |
|
Nanotechnology Stocks To Add to Your Watchlist – August 30thSeptember 1 - ETF Daily News |
|
Top Nanotechnology Stocks To Follow Today – August 25thAugust 27 - ETF Daily News |
Controlled Release Drug Delivery Market and Clinical Pipeline Report: A $90 Billion Opportunity in Controlled Release Drug Delivery by 2030August 26 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 0 | 3.2M | -3.2M | -2.4M | -4.9M | |
| Q2 '24 | 0 | 2.2M | -2.2M | -3.3M | -3.2M | |
| Q1 '24 | 0 | 1.1M | -1.1M | -1.7M | -2.1M | |
| Q4 '23 | 83,000 | 2.3M | -2.2M | -3.5M | -2.3M | |
| Q3 '23 | 42,000 | 1.1M | -1.1M | -1.8M | -1.1M |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Biodexa Pharmaceuticals (BDRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Biodexa Pharmaceuticals?
The Market Cap of Biodexa Pharmaceuticals is $3.5M.
What is Biodexa Pharmaceuticals' PE Ratio?
As of today, Biodexa Pharmaceuticals' PE (Price to Earnings) ratio is 0.
What is the current stock price of Biodexa Pharmaceuticals?
Currently, the price of one share of Biodexa Pharmaceuticals stock is $5.93.
How can I analyze the BDRX stock price chart for investment decisions?
The BDRX stock price chart above provides a comprehensive visual representation of Biodexa Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biodexa Pharmaceuticals shares. Our platform offers an up-to-date BDRX stock price chart, along with technical data analysis and alternative data insights.
Does BDRX offer dividends to its shareholders?
As of our latest update, Biodexa Pharmaceuticals (BDRX) does not offer dividends to its shareholders. Investors interested in Biodexa Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Biodexa Pharmaceuticals?
Some of the similar stocks of Biodexa Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.